Biomarker ID | 821 |
PMID | 22127895 |
Year | 2012 |
Biomarker | Methylation Status of AIM1 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Decreased hypermethylation in progression |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR = 0.4 (95% CI: 0.18-0.89) ; Multivariate: HR = 0.45 (95% CI: 0.2, 1.0) |
Effect on Pathways | NA |
Experiment | Time To Progression |
Type of Biomarker | Prognostic |
Cohort | 95 prostate cancer patients all with a Gleason score of 3 + 4 = 7 and a minimum follow-up period of 8 years. 48 patients had experienced recurrence |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Univariate: p = 0.02 ; Multivariate: p = 0.05 |
Method Used | Quantitative Methylation Specific PCR (QMSP) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CRYBG1 |